Trofinetide (NNZ-2566) / DAYBUE™
Rett Syndrome
Key Facts
About Neuren Pharmaceuticals
Neuren Pharmaceuticals is a public biotech company listed on the Australian Securities Exchange (ASX: NEU) that specializes in discovering and developing treatments for serious neurological disorders. Its primary achievement is the U.S. FDA approval and commercialization of trofinetide for Rett syndrome, a landmark event driven by a strategic partnership with Acadia Pharmaceuticals. The company's strategy involves leveraging its expertise in neurotrophic factors to expand its pipeline into other rare, high-need conditions with significant unmet medical needs.
View full company profileTherapeutic Areas
Other Rett Syndrome Drugs
| Drug | Company | Phase |
|---|---|---|
| DAYBUE® (trofinetide) | Acadia Pharmaceuticals | Approved/Commercial |
| TSHA-102 | Taysha Gene Therapies | Phase 1/2 |
| ANAVEX®2-73 (blarcamesine) | Anavex Life Sciences | Phase 2/3 |
| NGN-401 | Neurogene | Phase 1/2 |